A 7196 (see companion bill S 5169) – New York
Introduced: 2019 Status: Inactive / Dead
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
A 7245 (see companion bill S 4370) – New York
Introduced: 2021 Status: In Process
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, is to …
A 8824 (see companion bill S 398) – New York
Introduced: 2022 Status: In Process
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
AB 824 – California
Introduced: 2019 Status: Enacted
Business: preserving access to affordable drugs – This bill would provide that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical …
H 4605 (replaced by H4617) – Massachusetts
Introduced: 2018 Status: Inactive / Dead
AN ACT ESTABLISHING THE HONORABLE PETER V. KOCOT ACT TO ENHANCE ACCESS TO HIGH QUALITY, AFFORDABLE AND TRANSPARENT HEALTHCARE IN THE COMMONWEALTH.
H 4617 (replacd by H 4639) – Massachusetts
Introduced: 2018 Status: Inactive / Dead
AN ACT ESTABLISHING THE HONORABLE PETER V. KOCOT ACT TO ENHANCE ACCESS TO HIGH QUALITY, AFFORDABLE AND TRANSPARENT HEALTHCARE IN THE COMMONWEALTH.
H 4639 – Massachusetts
Introduced: 2018 Status: Inactive / Dead
AN ACT ESTABLISHING THE HONORABLE PETER V. KOCOT ACT TO ENHANCE ACCESS TO HIGH QUALITY, AFFORDABLE AND TRANSPARENT HEALTHCARE IN THE COMMONWEALTH.
HB 2529 (see companion bill SB 241) – Texas
Introduced: 2023 Status: Inactive / Dead
Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.
HB 2754 – Oregon
Introduced: 2019 Status: Inactive / Dead
Requires pharmacy or pharmacist to substitute prescribed biological product with interchangeable biological product. Declares emergency, effective on passage.
HB 345 – Montana
Introduced: 2021 Status: Inactive / Dead
Establish Prescription Drug Pay-for-Delay Transparency Act. Each manufacturer of a brand-name prescription drug that is transacting business in this state or whose brand-name prescription drugs are otherwise sold or distributed in this state shall notify …
HB 6619 – Connecticut
Introduced: 2023 Status: Inactive / Dead
An Act concerning prohibiting pay for delay. To preserve consumer access to affordable generic drugs.
HB 7174 – Connecticut
Introduced: 2019 Status: Inactive / Dead
To: (1) Establish the “Connecticut Prescription Drug Program” and the “Connecticut prescription drug program account”; (2) require pharmaceutical manufacturers to send notice to the Insurance Commissioner regarding “pay-for-delay” agreements, and require health carriers and pharmacy …
LD 1280 (see companion bill SP 432) – Maine
Introduced: 2017 Status: Enacted Year Enacted: 2018
AN ACT REGARDING GENERIC DRUG PRICING. This bill amends the Maine Pharmacy Act to require that a drug distributed in this State must be made available for sale in this State to a person seeking …
S 398 (see companion bill A 8824) – New York
Introduced: 2022 Status: In Process
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
S 4370 (see companion bill A 7245) – New York
Introduced: 2021 Status: In Process
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, is to …
S 5169 (see companion bill A 7196) – New York
Introduced: 2019 Status: Inactive / Dead
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.